These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 22439669)

  • 21. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasagiline.
    Siddiqui MA; Plosker GL
    Drugs Aging; 2005; 22(1):83-91; discussion 93-4. PubMed ID: 15663351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rasagiline for the treatment of Parkinson's disease: an update.
    Stocchi F; Fossati C; Torti M
    Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
    Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
    Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on rasagiline in Parkinson's disease.
    Oldfield V; Keating GM; Perry CM
    CNS Drugs; 2008; 22(1):83-6. PubMed ID: 18072817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
    Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
    Hauser RA; Abler V; Eyal E; Eliaz RE
    Int J Neurosci; 2016 Oct; 126(10):942-6. PubMed ID: 26988747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
    Jiang DQ; Wang HK; Wang Y; Li MX; Jiang LL; Wang Y
    Neurol Sci; 2020 Jan; 41(1):101-109. PubMed ID: 31446579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
    Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
    N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
    Rinaldi D; Assogna F; Sforza M; Tagliente S; Pontieri FE
    Neurol Sci; 2018 Jan; 39(1):141-143. PubMed ID: 28956175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
    Elmer LW; Bertoni JM
    Expert Opin Pharmacother; 2008 Nov; 9(16):2759-72. PubMed ID: 18937611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
    Chang Y; Wang LB; Li D; Lei K; Liu SY
    Ann Med; 2017 Aug; 49(5):421-434. PubMed ID: 28293967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect
    Nagai M; Hattori N
    Nihon Yakurigaku Zasshi; 2020; 155(3):187-194. PubMed ID: 32378642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.